California SB40 aims to reduce the financial burden of insulin for people with diabetes by capping cost-sharing at $35 for a 30-day supply.

California SB40 addresses the high cost of insulin by imposing a $35 cap on cost-sharing for a 30-day supply of insulin for individuals and small groups, effective January 1, 2027. The bill also mandates coverage for essential diabetes management equipment and supplies, including blood glucose monitors, insulin pumps, and syringes, without requiring a prescription. Additionally, it prohibits step therapy protocols for insulin prescriptions, ensuring immediate access to necessary insulin types.

California SB40 aims to reduce the financial burden of insulin for people with diabetes by capping cost-sharing at $35 for a 30-day supply.

California SB40 addresses the high cost of insulin by imposing a $35 cap on cost-sharing for a 30-day supply of insulin for individuals and small groups, effective January 1, 2027. The bill also mandates coverage for essential diabetes management equipment and supplies, including blood glucose monitors, insulin pumps, and syringes, without requiring a prescription. Additionally, it prohibits step therapy protocols for insulin prescriptions, ensuring immediate access to necessary insulin types.